Aspire Growth Partners LLC Takes $376,000 Position in DexCom, Inc. (NASDAQ:DXCM)

Aspire Growth Partners LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 4,834 shares of the medical device company's stock, valued at approximately $376,000.

Several other hedge funds and other institutional investors also recently modified their holdings of DXCM. Watts Gwilliam & Co. LLC acquired a new position in shares of DexCom during the fourth quarter valued at approximately $3,334,000. Congress Asset Management Co. increased its position in shares of DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the period. Janney Montgomery Scott LLC raised its stake in shares of DexCom by 2,226.6% in the 4th quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock worth $18,085,000 after buying an additional 222,548 shares in the last quarter. First Hawaiian Bank lifted its holdings in shares of DexCom by 556.1% in the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company's stock valued at $1,801,000 after buying an additional 19,629 shares during the period. Finally, Proficio Capital Partners LLC bought a new position in DexCom during the fourth quarter valued at about $5,812,000. Institutional investors and hedge funds own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Redburn Atlantic raised DexCom from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Canaccord Genuity Group increased their price target on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a research report on Friday. Piper Sandler cut their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a report on Friday. Finally, Robert W. Baird dropped their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $98.11.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares in the company, valued at $7,432,268.76. This represents a 10.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the completion of the transaction, the executive vice president now owns 135,482 shares of the company's stock, valued at $10,002,636.06. This represents a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,926 shares of company stock valued at $4,734,384. Corporate insiders own 0.32% of the company's stock.

DexCom Trading Up 1.7 %

DXCM traded up $1.35 during trading on Tuesday, reaching $81.62. 5,200,570 shares of the company's stock were exchanged, compared to its average volume of 4,284,210. The company's fifty day moving average price is $71.27 and its 200-day moving average price is $76.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market capitalization of $32.00 billion, a PE ratio of 57.07, a P/E/G ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. DexCom's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the business posted $0.32 EPS. As a group, equities analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.